Irish Chamber Board Member, Eric Karas, is a recognized commercial leader in the biopharmaceutical industry with more than 25 years of sales, marketing, market access, and strategic planning experience across multiple specialty product launches.
Mr. Karas was recently appointed Chief Commercial Officer with ARS Pharma. Prior he was Vice President & General Manager of Commercial, North America at Emergent BioSolutions. He also led commercial initiatives for NARCAN® Nasal Spray at Adapt Pharmaceutical, which was acquired by Emergent in 2018. Before Adapt Pharmaceutical, Mr. Karas was credited with being at the forefront of Auxilium Pharmaceuticals’ growth during his 8-year tenure and overseeing all global commercial objectives related to its urology portfolio. He also led the launch readiness planning and go-to-market strategy for the launch of XIAFLEX® for Peyronie’s disease. Auxilium was acquired in 2015 by Endo Pharmaceuticals.
Mr. Karas also has held cross-functional roles in government affairs, public relations, patient advocacy, and sales leadership roles at Astellas, Bristol-Myers Squibb, and Merck. Industry associations have also recognized him for numerous disease awareness and branded campaigns targeting HCPs and consumers.
Mr. Karas received his MBA in Integrated Management from Michigan State University, Broad School of Management, and a Bachelor of Science in Accounting from Rutgers University.